New drug could be cure for common cause of high blood pressure
EU medicines panel recommends AstraZeneca's baxdrostat for uncontrolled hypertension, while new research suggests a potential cure for hormone-driven high blood pressure.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending marketing authorization for Baxfendy, the brand name for baxdrostat, developed by AstraZeneca for the treatment of adults with hypertension. AstraZeneca's own announcement confirms the recommendation for uncontrolled hypertension, while Securities.io and marketscreener.com report the same positive opinion from the EU panel. Separately, News-Medical reports on new research indicating a treatment that may offer a lasting cure for hormone-related hypertension, though the coverage does not specify whether this research is directly connected to baxdrostat or represents a distinct therapeutic approach. Hansoh Pharmaceutical's Aumseqa also received further consideration from the CHMP during the same meeting, according to Fierce Pharma.
Coverage emphasizes the regulatory milestone for AstraZeneca's aldosterone synthase inhibitor, with multiple financial and pharmaceutical trade outlets tracking the CHMP opinion as a pivotal step toward European market access. Reuters and the EMA's official highlights provide the primary regulatory confirmation, while AstraZeneca's corporate announcement frames the recommendation for uncontrolled hypertension specifically. Fierce Pharma adds context by noting the simultaneous developments for Hansoh's Aumseqa. News-Medical's reporting on a potential cure for hormone-related hypertension introduces a separate scientific thread that may intersect with the aldosterone-targeting mechanism of baxdrostat, though the headlines do not establish a direct link. London South East and Mirage News replicate the corporate announcement, while marketscreener.com and Securities.io frame the news for investor audiences.
The background context centers on the role of aldosterone excess in resistant and uncontrolled hypertension, a condition where standard multi-drug regimens fail to achieve blood pressure targets. Baxdrostat operates as an aldosterone synthase inhibitor, targeting the enzymatic pathway responsible for aldosterone production. The CHMP recommendation follows clinical evaluation of the compound's efficacy and safety profile in this patient population. The News-Medical report on a potential lasting cure for hormone-related hypertension suggests ongoing research into definitive interventions beyond chronic suppression, possibly involving genetic, surgical, or novel molecular approaches. The parallel CHMP review of Hansoh's Aumseqa indicates competitive dynamics in the hypertension pipeline. Regulatory timelines in the EU typically see the European Commission adopt a final decision within two months of a CHMP positive opinion.
What to watch next includes the European Commission's formal adoption of the marketing authorization for Baxfendy, which would enable launch across EU member states. AstraZeneca's commercial rollout strategy and pricing negotiations with national health technology assessment bodies will determine real-world access. The News-Medical report's reference to a lasting cure warrants scrutiny of upcoming peer-reviewed publications or conference presentations to clarify the therapeutic modality and its relationship to existing aldosterone-targeted therapies. Hansoh's Aumseqa progress through the CHMP process bears monitoring for competitive positioning. Post-marketing safety surveillance requirements and real-world evidence generation plans for baxdrostat will likely be outlined in the European public assessment report once finalized.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: unsupported claims removed (95% supported) Updated 4d ago.
Quick answers
What is Baxfendy and who makes it?
Baxfendy is the brand name for baxdrostat, an aldosterone synthase inhibitor developed by AstraZeneca for the treatment of adults with hypertension, specifically uncontrolled hypertension according to the company's announcement.
What regulatory step has been completed?
The CHMP has issued a positive opinion recommending marketing authorization in the EU. The European Commission typically adopts a final decision within two months.
What does the News-Medical report describe?
News-Medical reports on new research suggesting a treatment that may offer a lasting cure for hormone-related hypertension, though the headlines do not specify the mechanism or its connection to baxdrostat.
Coverage (9)
- Europe's CHMP backs Baxfendy, gives Hansoh's Aumseqa another chance Fierce Pharma · 9d ago
- Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 November 2026 European Medicines Agency (EMA) · 9d ago
- Baxfendy (baxdrostat) recommended for approval in the EU for the treatment of adults with hypertension AstraZeneca · 9d ago
- CHMP Backs AstraZeneca’s Baxfendy for Uncontrolled Hypertension Securities.io · 9d ago
- EU panel backs AstraZeneca hypertension drug baxdrostat Reuters · 9d ago
- Baxfendy Recommended for EU Approval for Adult Hypertension Mirage News · 9d ago
- EU Medicines Agency Panel Issues Positive Opinion on AstraZeneca's Hypertension Drug marketscreener.com · 9d ago
- AstraZeneca says Baxfendy recommended for EU approval London South East · 9d ago
- New treatment may offer lasting cure for hormone-related hypertension News-Medical · 9d ago
Topics
Related trends
New treatment may cure common hormonal cause of high blood pressure
A small study found that extended treatment with the aldosterone synthase inhibitor baxdrostat led to sustained blood pressure reduction for up to two years after patients stopped taking the drug.
Opportunistically Detecting Signs of Hypertension on a Consumer Smartwatch
Recent coverage examines how consumer smartwatches and AI might opportunistically detect signs of high blood pressure.
Exclusive | AstraZeneca Made $10 Billion Offer for Rhythm Pharmaceuticals
AstraZeneca reportedly made a $10 billion acquisition offer for obesity drugmaker Rhythm Pharmaceuticals.
AstraZeneca CEO strikes bullish tone on pipeline as stock rallies
AstraZeneca unveils a $1.5 billion savings drive, pledges no layoffs and sees profits surge, sparking a bullish CEO outlook and a share‑price rally.
Your Blood Pressure Could Be Higher Than You Think. These 7 Fruits May Help Bring It Down, Say Experts
Medical experts and dieticians are highlighting specific fruits and vegetables, including pomegranates and beetroots, to help lower high blood pressure.
Millions of people high blood pressure pills daily, now scientists are testing a small device that stimul
British researchers have tested a small ear-clip nerve stimulation device as a potential alternative to daily blood pressure medication.